Published in Mol Cancer Ther on August 11, 2009
Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev (2012) 1.18
Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment. J Med Chem (2011) 1.10
Cell-specific targeting by heterobivalent ligands. Bioconjug Chem (2011) 1.00
Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc Natl Acad Sci U S A (2012) 0.94
Synthetic receptors with antibody-like binding affinities. Curr Opin Chem Biol (2010) 0.93
Synthesis and evaluation of dimeric derivatives of 5-HT(2A) receptor (5-HT(2A)R) antagonist M-100907. ACS Chem Neurosci (2011) 0.92
A sucrose-derived scaffold for multimerization of bioactive peptides. Bioorg Med Chem (2011) 0.90
Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem Pharmacol (2010) 0.90
Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors. Bioorg Med Chem (2013) 0.89
Fluorescent and lanthanide labeling for ligand screens, assays, and imaging. Methods Mol Biol (2011) 0.89
Synthesis and characterization of a Eu-DTPA-PEGO-MSH(4) derivative for evaluation of binding of multivalent molecules to melanocortin receptors. Bioorg Med Chem Lett (2010) 0.89
Peptide heterodimers for molecular imaging. Amino Acids (2010) 0.86
Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy. J Med Chem (2012) 0.81
Synthesis and evaluation of cholecystokinin trimers: a multivalent approach to pancreatic cancer detection and treatment. Bioorg Med Chem Lett (2013) 0.81
NIR-activated content release from plasmon resonant liposomes for probing single-cell responses. ACS Nano (2012) 0.81
Expanding the utility of beta-galactosidase complementation: piece by piece. Mol Pharm (2010) 0.80
Trigonal scaffolds for multivalent targeting of melanocortin receptors. Org Biomol Chem (2015) 0.79
Design and applications of bispecific heterodimers: molecular imaging and beyond. Mol Pharm (2014) 0.78
Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016. Biochim Biophys Acta (2017) 0.78
Development of a time-resolved fluorescence probe for evaluation of competitive binding to the cholecystokinin 2 receptor. Bioorg Med Chem (2015) 0.75
Peptides and peptidomimetics as immunomodulators. Immunotherapy (2014) 0.75
A Synthetic Heterobivalent Ligand Composed of Glucagon-Like Peptide 1 and Yohimbine Specifically Targets β Cells Within the Pancreas. Mol Imaging Biol (2015) 0.75
Synthesis and bioactivity of MSH4 oligomers prepared by an A2 + B2 strategy. Tetrahedron Lett (2015) 0.75
Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5. Mol Pharm (2016) 0.75
Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov (2006) 3.08
Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J Am Chem Soc (2002) 2.94
Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr Opin Chem Biol (2000) 2.57
Oligomerization of G protein-coupled receptors: past, present, and future. Biochemistry (2004) 2.03
Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets (2004) 1.86
Target discovery. Nat Rev Drug Discov (2003) 1.77
G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ Res (2004) 1.66
Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Anal Biochem (2004) 1.66
New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology (1997) 1.61
Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH. Bioorg Med Chem Lett (2004) 1.58
Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through extracellular signal-regulated kinase signaling in rat solitary nucleus. Endocrinology (2005) 1.53
Modulation of hexokinase association with mitochondria analyzed with quantitative three-dimensional confocal microscopy. J Cell Biol (1991) 1.52
Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem (2004) 1.39
Her-2/neu and breast cancer. Diagn Mol Pathol (2001) 1.38
Understanding recombinant expression of membrane proteins. Curr Opin Biotechnol (2006) 1.38
Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl (2008) 1.36
Targeting drugs to combinations of receptors: a modeling analysis of potential specificity. Ann Biomed Eng (2005) 1.31
Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem (2007) 1.31
G protein-coupled receptor signalling and cross-talk: achieving rapidity and specificity. Cell Signal (2002) 1.30
Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Mol Pharmacol (2005) 1.29
Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods (2001) 1.28
The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. J Biol Chem (2005) 1.27
Development of a lanthanide-based assay for detection of receptor-ligand interactions at the delta-opioid receptor. Anal Biochem (2005) 1.25
Targeted therapies for cancer 2004. Am J Clin Pathol (2004) 1.23
Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. Proc Natl Acad Sci U S A (1996) 1.23
Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin Ther Targets (2003) 1.19
Binding of multivalent carbohydrates to concanavalin A and Dioclea grandiflora lectin. Thermodynamic analysis of the "multivalency effect". J Biol Chem (2000) 1.17
Heterologous expression of G-protein-coupled receptors. Trends Biotechnol (1996) 1.12
Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat (2003) 1.11
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10
The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology. FEBS J (2005) 1.06
Overview of targeted therapies for cancer. Am J Health Syst Pharm (2003) 1.03
Detection of promoter activity by flow cytometric analysis of GFP reporter expression. Nucleic Acids Res (2002) 1.01
A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel (2005) 1.00
Design of improved membrane protein production experiments: quantitation of the host response. Protein Sci (2005) 0.98
Effects of oral preload, CCK or bombesin administration on short term food intake of melanocortin 4-receptor knockout (MC4RKO) mice. Peptides (2006) 0.92
Optimisation and evaluation of a high-throughput mammalian protein expression system. Protein Expr Purif (2005) 0.89
Metabolic modulation of hexokinase association with mitochondria in living smooth muscle cells. Am J Physiol (1996) 0.88
Selection of peptides for specific delivery of oligonucleotides into cancer cells. Methods Mol Biol (2004) 0.85
Effects of C-terminal truncation of the recombinant delta-opioid receptor on phospholipase C and adenylyl cyclase coupling. J Neurochem (1998) 0.83
The promise of targeted therapy: cancer drugs become more specific. Cleve Clin J Med (2004) 0.81
Enrichment of transiently transfected mesangial cells by cell sorting after cotransfection with GFP. Am J Physiol (1999) 0.81
The inhibition of lung cancer cell growth by intracellular immunization with LC-1 ScFv. Cell Res (2002) 0.79
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
A microenvironmental model of carcinogenesis. Nat Rev Cancer (2008) 4.40
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res (2006) 3.90
Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res (2009) 3.40
Adaptive therapy. Cancer Res (2009) 2.81
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Acidity generated by the tumor microenvironment drives local invasion. Cancer Res (2013) 2.63
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39
The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A (2003) 2.29
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (2005) 2.17
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Tumor pH and its measurement. J Nucl Med (2010) 2.08
Renal and systemic pH imaging by contrast-enhanced MRI. Magn Reson Med (2003) 2.05
L-DOPA is an endogenous ligand for OA1. PLoS Biol (2008) 2.03
High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magn Reson Med (2006) 1.97
Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol (2007) 1.94
Antinociceptive and nociceptive actions of opioids. J Neurobiol (2004) 1.93
The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res (2009) 1.92
Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets (2004) 1.86
In vivo detection of neuroarchitecture in the rodent brain using manganese-enhanced MRI. Neuroimage (2004) 1.85
Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res (2009) 1.84
In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng (2005) 1.78
Imaging pH and metastasis. NMR Biomed (2011) 1.67
PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther (2005) 1.67
Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Anal Biochem (2004) 1.66
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 1.65
Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer (2011) 1.64
Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia (2003) 1.63
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res (2005) 1.62
Metabolic changes during carcinogenesis: potential impact on invasiveness. J Theor Biol (2006) 1.59
Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH. Bioorg Med Chem Lett (2004) 1.58
Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol (2003) 1.57
Quantitative imaging in cancer evolution and ecology. Radiology (2013) 1.55
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther (2005) 1.54
Parallel synthesis and biological evaluation of different sizes of bicyclo[2,3]-Leu-enkephalin analogues. Biopolymers (2005) 1.54
Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia (2005) 1.54
Lateral phase separation in lipid-coated microbubbles. Langmuir (2006) 1.52
Of cancer and cave fish. Nat Rev Cancer (2011) 1.50
Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain (2005) 1.49
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia (2005) 1.45
Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis (2008) 1.44
Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges". Int J Cancer (2014) 1.44
Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm (2011) 1.42
Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem (2006) 1.40
Imaging the extracellular pH of tumors by MRI after injection of a single cocktail of T1 and T2 contrast agents. NMR Biomed (2011) 1.40
Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem (2005) 1.38
Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol (2003) 1.38
Monomethylarsonous acid induces transformation of human bladder cells. Toxicol Appl Pharmacol (2006) 1.38
Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res (2012) 1.38
Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol (2008) 1.37
Automated Delineation of Lung Tumors from CT Images Using a Single Click Ensemble Segmentation Approach. Pattern Recognit (2013) 1.36
Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS One (2011) 1.36
Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl (2008) 1.36
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia (2002) 1.32
Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem (2007) 1.31
Comparison of the contributions of the nuclear and cytoplasmic compartments to global gene expression in human cells. BMC Genomics (2007) 1.30
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res (2009) 1.29
Systemic buffers inhibit carcinogenesis in TRAMP mice. J Urol (2012) 1.28
Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain. Bioorg Med Chem (2009) 1.28
Development of a lanthanide-based assay for detection of receptor-ligand interactions at the delta-opioid receptor. Anal Biochem (2005) 1.25
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther (2004) 1.24
Rhodopsin reconstituted into a planar-supported lipid bilayer retains photoactivity after cross-linking polymerization of lipid monomers. J Am Chem Soc (2005) 1.24
Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia (2008) 1.23
Targeting Aurora-2 kinase in cancer. Mol Cancer Ther (2003) 1.23
Thermostability of firefly luciferases affects efficiency of detection by in vivo bioluminescence. Mol Imaging (2004) 1.23
Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett (2006) 1.23
A stimulus-responsive contrast agent for ultrasound molecular imaging. Biomaterials (2007) 1.22
Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem (2007) 1.21
Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem (2007) 1.21
Reduction of metastasis using a non-volatile buffer. Clin Exp Metastasis (2011) 1.21
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. J Am Chem Soc (2010) 1.20
Evolutionary dynamics of cancer prevention. Nat Rev Cancer (2010) 1.20
Rigid linkers for bioactive peptides. Bioconjug Chem (2006) 1.19
Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin Ther Targets (2003) 1.19
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med (2013) 1.19
Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res (2012) 1.19